Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 7 | 2024 | 157 | 1.310 |
Why?
|
| Liver Transplantation | 5 | 2024 | 1193 | 0.530 |
Why?
|
| Colonoscopy | 3 | 2014 | 303 | 0.440 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 272 | 0.410 |
Why?
|
| Colonoscopes | 2 | 2011 | 13 | 0.410 |
Why?
|
| Adenoma | 2 | 2011 | 258 | 0.350 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 35 | 0.300 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 578 | 0.300 |
Why?
|
| Rifamycins | 1 | 2016 | 7 | 0.250 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 144 | 0.250 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.250 |
Why?
|
| Education, Medical, Graduate | 3 | 2024 | 425 | 0.250 |
Why?
|
| Esophageal Fistula | 1 | 2006 | 12 | 0.240 |
Why?
|
| Pericardial Effusion | 1 | 2006 | 16 | 0.240 |
Why?
|
| Cardiac Tamponade | 1 | 2006 | 19 | 0.240 |
Why?
|
| Liver Diseases | 3 | 2021 | 243 | 0.230 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 85 | 0.230 |
Why?
|
| Hepatitis C | 2 | 2021 | 181 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 618 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2021 | 364 | 0.210 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 343 | 0.200 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.200 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 339 | 0.180 |
Why?
|
| Curriculum | 3 | 2021 | 590 | 0.180 |
Why?
|
| Internship and Residency | 3 | 2021 | 1074 | 0.170 |
Why?
|
| Viremia | 1 | 2021 | 51 | 0.170 |
Why?
|
| United States | 8 | 2024 | 7581 | 0.170 |
Why?
|
| Gastroenterologists | 1 | 2021 | 31 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2020 | 18 | 0.160 |
Why?
|
| Donor Selection | 1 | 2021 | 81 | 0.160 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2020 | 24 | 0.160 |
Why?
|
| Internal Medicine | 2 | 2021 | 327 | 0.160 |
Why?
|
| Clinical Competence | 4 | 2021 | 810 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2021 | 187 | 0.150 |
Why?
|
| Middle Aged | 12 | 2021 | 27535 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 19 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2021 | 541 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 32 | 0.130 |
Why?
|
| Male | 15 | 2021 | 44355 | 0.130 |
Why?
|
| Humans | 22 | 2024 | 93132 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Students, Medical | 1 | 2021 | 433 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 53 | 0.120 |
Why?
|
| Adult | 11 | 2021 | 27849 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 55 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 496 | 0.110 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 239 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 416 | 0.110 |
Why?
|
| Education, Medical | 1 | 2017 | 227 | 0.110 |
Why?
|
| Liver Failure | 1 | 2015 | 69 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 97 | 0.110 |
Why?
|
| Esophagitis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Female | 13 | 2021 | 48542 | 0.100 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 9 | 0.100 |
Why?
|
| Ammonia | 1 | 2014 | 34 | 0.100 |
Why?
|
| Hyperammonemia | 1 | 2014 | 14 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 97 | 0.100 |
Why?
|
| Glycerol | 1 | 2014 | 33 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 448 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 156 | 0.100 |
Why?
|
| Hospitalization | 2 | 2016 | 924 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 458 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 176 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 773 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 191 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 236 | 0.090 |
Why?
|
| Young Adult | 3 | 2020 | 6922 | 0.090 |
Why?
|
| Hospitalists | 1 | 2014 | 135 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2014 | 376 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2014 | 292 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 37 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2010 | 187 | 0.080 |
Why?
|
| Adolescent | 2 | 2020 | 9550 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2010 | 135 | 0.080 |
Why?
|
| Aged | 8 | 2016 | 20395 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2016 | 709 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 371 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 5380 | 0.070 |
Why?
|
| Career Choice | 2 | 2021 | 153 | 0.070 |
Why?
|
| Graft Survival | 2 | 2021 | 939 | 0.060 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 67 | 0.060 |
Why?
|
| Viral Load | 2 | 2021 | 154 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2016 | 10128 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2021 | 285 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2021 | 9070 | 0.060 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 73 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 1004 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2016 | 114 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 888 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7039 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5900 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 941 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1519 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1925 | 0.040 |
Why?
|
| Incidence | 1 | 2016 | 1697 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2021 | 2434 | 0.040 |
Why?
|
| Program Development | 1 | 2021 | 129 | 0.040 |
Why?
|
| Educational Status | 1 | 2021 | 195 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1910 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 984 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1073 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 236 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 366 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 595 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 833 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 400 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 688 | 0.030 |
Why?
|
| Income | 1 | 2016 | 86 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3814 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 67 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 248 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 288 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 570 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 151 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 300 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 135 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 53 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 413 | 0.030 |
Why?
|
| Glutamine | 1 | 2014 | 93 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 482 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 494 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 480 | 0.020 |
Why?
|
| Urban Population | 1 | 2014 | 234 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 874 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 820 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 237 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1909 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 396 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 341 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1945 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1102 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 394 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1529 | 0.020 |
Why?
|
| Physicians | 1 | 2017 | 668 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 618 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 88 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 291 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1727 | 0.020 |
Why?
|
| Disposable Equipment | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 706 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12230 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1452 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1898 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 504 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2010 | 137 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 411 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 981 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 753 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 888 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 3044 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1240 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 1866 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 27973 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 4546 | 0.010 |
Why?
|